Luciana C Veiras1, DuoYao Cao1, Suguru Saito1, Zhenzi Peng1, Ellen A Bernstein1, Justin Z Y Shen1, Maya Koronyo-Hamaoui1,2, Derick Okwan-Duodu1,3, Jorge F Giani1,3, Zakir Khan1,3, Kenneth E Bernstein4,5. 1. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. 2. Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. 3. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Davis Research Building, Rm 2021, 110 N George Burns Rd., Los Angeles, CA, 90048, USA. 4. Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Kenneth.Bernstein@cshs.org. 5. Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Davis Research Building, Rm 2021, 110 N George Burns Rd., Los Angeles, CA, 90048, USA. Kenneth.Bernstein@cshs.org.
Abstract
PURPOSE OF REVIEW: To review recent studies exploring how myeloid cell overexpression of angiotensin-converting enzyme (ACE) affects the immune response and to formulate an approach for considering the effectiveness of inflammation in cardiovascular disease RECENT FINDINGS: While it is widely appreciated that the renin-angiotensin system affects aspects of inflammation through the action of angiotensin II, new studies reveal a previously unknown role of ACE in myeloid cell biology. This was apparent from analysis of two mouse lines genetically modified to overexpress ACE in monocytes/macrophages or neutrophils. Cells overexpressing ACE demonstrated an increased immune response. For example, mice with increased macrophage ACE expression have increased resistance to melanoma, methicillin-resistant Staphylococcus aureus, a mouse model of Alzheimer's disease, and ApoE-knockout-induced atherosclerosis. These data indicate the profound effect of increasing myeloid cell function. Further, they suggest that an appropriate way to evaluate inflammation in both acute and chronic diseases is to ask whether the inflammatory infiltrate is sufficient to eliminate the immune challenge. The expression of ACE by myeloid cells induces a heightened immune response by these cells. The overexpression of ACE is associated with immune function beyond that possible by wild type (WT) myeloid cells. A heightened immune response effectively resolves disease in a variety of acute and chronic models of disease including models of Alzheimer's disease and atherosclerosis.
PURPOSE OF REVIEW: To review recent studies exploring how myeloid cell overexpression of angiotensin-converting enzyme (ACE) affects the immune response and to formulate an approach for considering the effectiveness of inflammation in cardiovascular disease RECENT FINDINGS: While it is widely appreciated that the renin-angiotensin system affects aspects of inflammation through the action of angiotensin II, new studies reveal a previously unknown role of ACE in myeloid cell biology. This was apparent from analysis of two mouse lines genetically modified to overexpress ACE in monocytes/macrophages or neutrophils. Cells overexpressing ACE demonstrated an increased immune response. For example, mice with increased macrophage ACE expression have increased resistance to melanoma, methicillin-resistant Staphylococcus aureus, a mouse model of Alzheimer's disease, and ApoE-knockout-induced atherosclerosis. These data indicate the profound effect of increasing myeloid cell function. Further, they suggest that an appropriate way to evaluate inflammation in both acute and chronic diseases is to ask whether the inflammatory infiltrate is sufficient to eliminate the immune challenge. The expression of ACE by myeloid cells induces a heightened immune response by these cells. The overexpression of ACE is associated with immune function beyond that possible by wild type (WT) myeloid cells. A heightened immune response effectively resolves disease in a variety of acute and chronic models of disease including models of Alzheimer's disease and atherosclerosis.
Authors: Derick Okwan-Duodu; Daiana Weiss; Zhenzi Peng; Luciana C Veiras; Duo-Yao Cao; Suguru Saito; Zakir Khan; Ellen A Bernstein; Jorge F Giani; W Robert Taylor; Kenneth E Bernstein Journal: Biochem Biophys Res Commun Date: 2019-10-12 Impact factor: 3.575
Authors: J R Hagaman; J S Moyer; E S Bachman; M Sibony; P L Magyar; J E Welch; O Smithies; J H Krege; D A O'Brien Journal: Proc Natl Acad Sci U S A Date: 1998-03-03 Impact factor: 11.205
Authors: Kenneth E Bernstein; Yosef Koronyo; Brenda C Salumbides; Julia Sheyn; Lindsey Pelissier; Dahabada H J Lopes; Kandarp H Shah; Ellen A Bernstein; Dieu-Trang Fuchs; Jeff J-Y Yu; Michael Pham; Keith L Black; Xiao Z Shen; Sebastien Fuchs; Maya Koronyo-Hamaoui Journal: J Clin Invest Date: 2014-03 Impact factor: 14.808
Authors: Jing Wang; Chongxiu Sun; Norbert Gerdes; Conglin Liu; Mengyang Liao; Jian Liu; Michael A Shi; Aina He; Yi Zhou; Galina K Sukhova; Huimei Chen; Xian Wu Cheng; Masafumi Kuzuya; Toyoaki Murohara; Jie Zhang; Xiang Cheng; Mengmeng Jiang; Gary E Shull; Shaunessy Rogers; Chao-Ling Yang; Qiang Ke; Sabina Jelen; René Bindels; David H Ellison; Petr Jarolim; Peter Libby; Guo-Ping Shi Journal: Nat Med Date: 2015-06-22 Impact factor: 53.440
Authors: Yang Dong; Yanmin Gao; Cheng Luo; Nengshun Wu; Zhounan Cheng; Anni Qiu; Yan Zhou; Wendi Zhang; Minjie Chu; Qing Chang Journal: Front Public Health Date: 2022-06-28
Authors: Leah R Zuroff; Tania Torbati; Nadav J Hart; Dieu-Trang Fuchs; Julia Sheyn; Altan Rentsendorj; Yosef Koronyo; Eric Y Hayden; David B Teplow; Keith L Black; Maya Koronyo-Hamaoui Journal: Front Immunol Date: 2020-07-16 Impact factor: 7.561
Authors: Rishi Trikha; Danielle Greig; Benjamin V Kelley; Zeinab Mamouei; Troy Sekimura; Nicolas Cevallos; Thomas Olson; Ameen Chaudry; Clara Magyar; Daniel Leisman; Alexandra Stavrakis; Michael R Yeaman; Nicholas M Bernthal Journal: Front Immunol Date: 2020-09-11 Impact factor: 7.561
Authors: Brian C Belyea; Araceli E Santiago; Wilson A Vasconez; Vidya K Nagalakshmi; Fang Xu; Theodore C Mehalic; Maria Luisa S Sequeira-Lopez; R Ariel Gomez Journal: Sci Rep Date: 2021-03-31 Impact factor: 4.379